Overview of Antimicro- Waller Flashcards

1
Q

Top 5 drugs:

A
Amoxicillin
Azithromycin
Amoxicillin-clavulanic acid
Trimethoprim-sulfamethoxazole
Ciprofloxacin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

antibiotic Misuse may occur in a variety of ways:

A

Given when not needed
Continued when no longer necessary
Given at the wrong dose
Broad spectrum agents used for very susceptible bacteria
The wrong antibiotic given to treat infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

inappropriate prescribing

A
Over 50% of antibiotic prescribing may be inappropriate
Most of this inappropriate use is for:
Acute respiratory infections
Pharyngitis
Sinusitis
Bronchitis

Antibiotics are a common cause of ADE-related ED visits, accounting for:
7 of top 15 drugs in pediatric patients ADE-ED visits
1 of 5 ADE-related visits to ED in adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

A 37 y/o female with poorly controlled type 1 diabetes and end-stage renal disease, on hemodialysis, presents to the ED with 3-day history of dyspnea, cough with purulent sputum production, and intermittent fever.

She recently completed a course of meropenem for catheter-associated blood-stream infection 2 weeks ago.

Physical and laboratory findings are consistent with pneumonia. She is admitted to the hospital.

Questions to ask yourself about anti-microbial therapyp

A

Ask yourself whether an antimicrobial agent is warranted:

Is an antimicrobial indicated based on clinical findings? yes
Have appropriate cultures been obtained?
What is the most likely causative organism?-
What must be done to prevent secondary exposure?- not likely to have a 2ndary exposure in this case,

Is there clinical evidence or established guidelines that have determined antimicrobial therapy provides a clinical benefit?- yes, esp. for pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

A 37 y/o female with a history of end-stage renal disease, on dialysis, is admitted to the hospital with pneumonia. Antibiotics are initiated to cover the most likely pathogen(s).

Types & Goals of Therapy?

A

Empiric therapy; we suspect common organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

A 68 y/o male presents for a total hip replacement. Prior to surgery, he is given one dose of cefazolin to prevent development of a surgical wound infection.

Types & Goals of Therapy?

A

Prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

A 37 y/o female with a history of end-stage renal disease, on dialysis, is admitted to the hospital with pneumonia. Cultures result with sensitive Pseudomonas, vancomycin (mostly for gram positive) discontinued.

Types & Goals of Therapy?

A

Definitive therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

An 8 y/o male presents to the ED with a perforated appendix. Antibiotics are initiated pre-operatively to reduce risk of intra-abdominal abscess & wound infection.

Types & Goals of Therapy?

A

pre-emptive; this patient already has appendicitis

to prevent abdominal abscess

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

A 75 y/o male presents for follow-up of prosthetic hip joint infection. He receives continued, low dose antimicrobial therapy as hip prosthesis was unable to be removed.

Types & Goals of Therapy?

A

Suppressive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Most valuable, time tested method for immediate ID of bacteria =

A

gram stain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

gram positive vs negative

A

neg- 2 cell membranes, LPS endotoxin

pos- thicker peptidoglycan layer, teichoic acid stabilizes peptidoglycan layer (rigid, provides structural shape)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

beta lactamase

A

an important resistance mechanism against beta lactam antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Susceptibility Testing

A

Susceptible
- Likely to inhibit pathogenic microorganism

Intermediate
- May be effective at higher dosage, more frequent administration, or in specific body site

Resistant
- Not effective at inhibiting growth of microorganism

Types of Susceptibility Tests:
Dilution Tests
Disk Diffusion
Gradient Diffusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Minimum inhibitory concentration (MIC)

A

lowest concentration of drug required to inhibit growth

Breakpoints established by Clinical and Laboratory Standards Institute (CLSI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antibacterial Spectrum

A

Narrow-spectrum
- Act on a single or a limited group of microorganisms

Extended-spectrum
- Active against gram-positive bacteria but also against significant number of gram-negative bacteria

Broad-spectrum
- Act on a wide variety of bacterial species, including both gram-positive and gram-negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bacteriostatic vs. Bactericidal

A

Bacteriostatic: arrests growth and replication of bacteria (limits spread of infection)

Bactericidal: kills bacterial

  • Concentration-dependent killing: rate and extent of killing increase with increasing drug concentrations
  • Time-dependent killing: activity continues as long as serum concentration above minimum bactericidal concentration

This concept is relative
Certain drugs are –cidal against specific bacteria while –static against others

Drug-drug enhancement or synergism
Gentamicin – ineffective against enterococci in the absence of a cell-wall inhibitor
Combining penicillin with gentamicin leads to bactericidal activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Antimicrobial Classification

A

Antimicrobials classified based on:
Class and spectrum of microorganisms it kills
Biochemical pathway it interferes with
Chemical structure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Sites of Antibacterial Action

A
Cell wall synthesis
Cell membrane synthesis
Protein synthesis
Nucleic acid metabolism
Function of topoisomerases
Folate synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

β-Lactams- MOA, list, resistance

A

cell wall inhibitors

Penicillins
Cephalosporins
Monobactam
Carbapenems

Time-dependent; structural analogs of D-Ala-D-Ala; covalently bind penicillin-binding proteins (PBPs), inhibit the last transpeptidation step in cell wall synthesis

Structural difference in PBPs
Decreased PBP affinity
Inability for drug to reach site of action (i.e. gram-negative organisms)
Active efflux pumps
Drug destruction/inactivation by B-lactamases

20
Q

β-Lactamase Inhibitors

A

Amoxicillin + clavulanic acid,
ticarcillin + clavulanic acid,
ampicillin + sulbactam,
piperacillin + tazobactam

MOA: prevent destruction of B-lactam antibiotics

21
Q

Fluoroquinolone Mechanism of Action

A

Concentration-dependent, targets bacterial DNA gyrase & topoisomerase IV. Prevents relaxation of positive supercoils

22
Q

Inhibitors of Protein Synthesis- areas of action

A

Formation of initiation complex
Amino-acid incorporation
Formation of peptide bond
Translocation

23
Q

Aminoglycosides MOA

A

blocks initiation of protein synthesis
blocks further translation and elicits premature termination
incorporation of incorrect amino acid

Bind 30S subunit

24
Q

Tetracyclines MOA

A

Bind 30S subunit

25
Q

Macrolides MOA

A

Bind 50S subunit

26
Q

Sulfonamides and Trimethoprim

A

Inhibit folic acid synthesis; block sequential steps in pathway.

27
Q

Natural Penicillins spectrum, use

A

Penicillin G (IV, IM), penicillin V (PO)

Spectrum: highly effective against gram-positive cocci (GPC) but easily hydrolyzed by penicillinase

Therapeutic Use: narrow-spectrum, Streptococcus pneumoniae pneumonia and meningitis. Penicillin V for Streptococcus pyogenes pharyngitis, toxic shock, viridians streptococci endocarditis if susceptible, syphilis

28
Q

Anti-Staphylococcal Penicillins spectrum, therapeutic use

A

Oxacillin (IV, IM), dicloxacillin (PO), nafcillin (IV, IM)

Spectrum: penicillinase resistant; agents of first choice for Staphylococcus aureus (MSSA) and Staphylococcus epidermidis (MSSE) that are not methicillin-resistant

Therapeutic Use: restricted to infections with known Staphylococcus sensitivity

29
Q

Aminopenicillins

A

extended spectrum

Ampicillin (PO, IV, IM), amoxicillin (PO)

Spectrum: extended-spectrum; extends beyond gram-positive to gram-negative (Haemophilus influenzae, Escherichia coli, Proteus mirabilis), Listeria monocytogenes, susceptible meningococci, enterococci

Therapeutic Use: upper respiratory tract infections (S. pyogenes, S. pneumoniae, H. influenzae), sinusitis, otitis media, enterococcal infections

30
Q

Antipseudomonal Penicillins

A

piperacillin (IV)- use with tazobactam

Spectrum: extends spectrum to Pseudomonas aeruginosa, Enterobacter, and Proteus spp.

Therapeutic Use: serious gram-negative infections, hospital acquired pneumonia (HAP), immunocompromised patients, bacteremia, burn infections, UTI

31
Q

Penicillins ADRs

A

Allergic reactions
Anaphylaxis
Nausea, vomiting, mild to severe diarrhea
Pseudomembranous colitis

32
Q

1st-Generation Cephalosporins spectrum and therapeutic uses

A

Cefazolin (IV, IM), cephalexin (PO)

Spectrum: good gram-positive coverage, modest gram-negative (covers Moraxella, E. coli, Klebsiella pneumoniae, P. mirabilis), orally active anaerobes

Therapeutic Use: skin and soft tissue infections (SSTIs), surgical prophylaxis

33
Q

2nd-Generation Cephalosporins spectrum and use

A

Cefoxitin (IV), cefuroxime (PO, IV, IM)

Spectrum: somewhat increased activity against gram-negative, but less active than 3rd-generation. Subset active against Bacteroides fragilis

Therapeutic Use: used in gram-negative mixed anaerobic (intra-abdominal infections, pelvic inflammatory disease, diabetic foot infections)

34
Q

3rd-Generation Cephalosporins MOA and uses

A

Ceftriaxone (IV, IM), ceftazidime (IV, IM)

Spectrum: less active against gram-positive, more active against Enterobacteriaceae (although resistance increasing due to B-lactamase producing strains)

Therapeutic Use: serious gram-negative infections (Klebsiella, Proteus, Providencia, Serratia, Haemophilus), ceftriaxone DOC for all forms of gonorrhea & severe Lyme’s disease; meningitis. Ceftazidime covers Pseudomonas

35
Q

4th-Generation Cephalosporin

A

Cefepime (IV, IM)

Spectrum: extends beyond 3rd-generation, useful in serious infections in hospitalized patients. Effective against Pseudomonas

Therapeutic Use: empirical treatment of nosocomial infections

36
Q

Cephalosporins ADRs

A

1% risk of cross-reactivity to penicillins

Diarrhea

37
Q

Carbapenems spectrum, use, ADRs

A

), meropenem (IV), ertapenem (IV, IM)

Spectrum: aerobes & anaerobes; gram-positive, Enterobacteriaceae, Pseudomonas, Acinetobacter. Stenotrophomonas maltophilia is resistant.

Therapeutic Use: UTI, lower respiratory tract infection (LRTI), intra-abdominal, gynecological, SSTI, bone and joint infections

ADRs:
Nausea/vomiting (1-20%), seizures (1.5%), hypersensitivity

38
Q

Monobactam spectrum, therapeutic use

A

Aztreonam (IV, IM, INH)

Spectrum: activity against gram-negative (Enterobacteriaceae, Pseudomonas, H. influenzae, gonococci), no activity against GPC or anaerobes

Therapeutic Use: patients who are allergic to B-lactams appear not to react to aztreonam  effective for gram-negative infections which would usually be treated with B-lactam

39
Q

Glycopeptides MOA, resistance, spectrum, ADRs

A

Vancomycin (PO, IV)

MOA: inhibits cell wall synthesis binding with high affinity to D-Ala-D-Ala terminal of cell wall precursor units.

Resistance: alteration of D-Ala-D-Ala target to D-alanyl-D-lactate or D-alanyl-D-serine which binds glycopeptides poorly. Intermediate resistance may also occur

Spectrum: broad gram-positive coverage – S. aureus (including MRSA), S. epidermidis (including MRSE), Streptococci, Bacillus, Corynebacterium spp., Actinomyces, Clostridium

Therapeutic Use: osteomyelitis, endocarditis, MRSA, Streptococcus, enterococci, CNS infections, bacteremia, orally for C. difficile

ADRs:
Macular skin rash, chills, fever, rash
Red-man syndrome (histamine release): extreme flushing, tachycardia, hypotension
Ototoxicity, nephrotoxicity - watch out with renal patients!

40
Q

Fluoroquinolones MOA, spectrum, therapeutic use, ADRs

A

MOA: concentration-dependent; targets bacterial DNA gyrase & topoisomerase IV.

Spectrum: E. coli, Salmonella, Shigella, Enterobacter, Campylobacter, Neisseria, Pseudomonas aeruginosa, S. aureus (not MRSA), limited coverage of Streptococcus spp.
Levofloxacin, moxifloxacin, “respiratory fluoroquinolones” cover Streptococcus spp.

Therapeutic Use: UTI, prostatitis, STI (chlamydia, Neisseria gonorrhoeae), traveler’s diarrhea, shigellosis, bone, joint, SSTI infections, diabetic foot infections

ADRs:
GI 3-17% (mild nausea, vomiting, abdominal discomfort)
CNS 0.9-11% (mild headache, dizziness, delirium, rare hallucinations)
Rash, photosensitivity, Achilles tendon rupture (CI in children)

41
Q

Aminoglycosides MOA, spectrum, therapeutic uses, ADRs

A

gentamicin (IV, IM, topical)

MOA: concentration-dependent (one high dose can do the trick); binds 30S ribosomal subunit, disrupts normal cycle of ribosomal function

Spectrum: aerobic gram-negative bacteria, limited action against gram-positive, synergistic bactericidal effects in gram-positive with cell wall active agent

Therapeutic Use: UTI (not uncomplicated), used if resistance to other agents, seriously ill patients, pneumonia (infective against S. pneumoniae and anaerobes), HAP, peritonitis, synergy in bacterial endocarditis, tobramycin inhalation in CF

ADRs:
Ototoxicity (may be as high as 25%)
Nephrotoxicity (8-26%)
Neuromuscular block and apnea

42
Q

Tetracyclines/Glycylcyclines MOA, spectrum,

A

doxycycline

MOA: bacteriostatic; binds 30S bacterial ribosome. Prevents access of aminoacyl tRNA to acceptor (A) site on mRNA ribosome complex

Spectrum: wide range of aerobic/anaerobic gram-positive and -negative activity; useful for atypical presentations and/or in outpatient setting

Therapeutic Use: CAP, atypical CAP coverage, community acquired SSTIs, community acquired MRSA, acne, Rickettsial infections (Rocky Mountain Spotted Fever), Q fever, anthrax

ADRs:
GI (epigastric burning, nausea, vomiting, diarrhea)
Superinfections of C. difficile
Photosensitivity
Teeth discoloration (it chelates calcium)
Thrombophlebitis

43
Q

Macrolides/Ketolides MOA, uses, etc.

A

Clarithromycin (PO), azithromycin (PO, IV, topical)

MOA: bacteriostatic; binds reversibly to 50S ribosomal subunit, inhibits translocation

Therapeutic Use: respiratory tract infections (spectrum S. pneumoniae, H. influenzae, and atypicals: Mycoplasma, Chalmydophilia, Legionella), alternative for otitis media, sinusitis, bronchitis, and SSTIs. Pertussis, gastroenteritis, H. pylori, Mycobacterial infections

ADRs:
GI (epigastric distress)
Hepatotoxicity
Arrhythmia
* QT prolongation

DDIs: CYP3A4 inhibition – prolongs effects of digoxin, warfarin….

44
Q

Lincosamides MOA, spectrum, uses

A

Clindamycin (PO, IV, IM, topical)

MOA: binds 50S subunit of bacterial ribosome, suppresses protein synthesis

Spectrum: pneumococci, S. pyogenes, viridans Streptococci, MSSA, *** anaerobes (B. fragilis)

Therapeutic Use: SSTIs, necrotizing SSTIs, lung abscesses, anaerobic lung and pleural space infections, topically for acne vulgaris

ADRs:
GI diarrhea
*** Pseudomembranous colitis Due to C. difficile
Skin rashes
Reversible increase in aminotransferase activity
May potentiate neuromuscular blockade

45
Q

Oxazolidinones

A

Linezolid (PO, IV)

MOA: inhibits protein synthesis binding P site of 50S ribosomal subunit, prevents formation of initiation complexes

Spectrum: gram-positive Staphylococcus (MSSA, MRSA, VRSA), Streptococcus (penicillin resistant S. pneumoniae), enterococci (VRE), gram-positive anaerobic cocci, gram-positive rods (Corynebacterium, L. monocytogenes)

Therapeutic Use: VRE faecium (SSTI, UTI, bacteremia), nosocomial pneumonia caused by MSSA and MRSA, CAP, complicated/uncomplicated SSTI infections

ADRs:
Myelosuppression [thrombocytopenia (2.4%),anemia, leukopenia]
Headache
Rash

DDIs: weak, nonspecific inhibitor of monoamine oxidase